ADPT:NSD-Adaptive Biotechnologies Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 45.01

Change

-0.82 (-1.79)%

Market Cap

USD 6.27B

Volume

0.43M

Average Target Price

USD 54.20 (+20.42%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-1.37 (-0.63%)

USD56.65B 21.08 16.42
REGN Regeneron Pharmaceuticals, Inc

-17.51 (-3.34%)

USD55.87B 20.76 16.02
MRNA Moderna, Inc

-2.47 (-2.44%)

USD39.98B N/A N/A
SGEN Seagen Inc

-3.44 (-2.05%)

USD30.08B 65.69 65.81
ALXN Alexion Pharmaceuticals, Inc

+0.50 (+0.41%)

USD26.83B 28.36 26.40
RPRX Royalty Pharma plc

-0.62 (-1.54%)

USD25.13B 23.05 9.48
BNTX BioNTech SE

-4.63 (-4.35%)

USD25.06B -99,999.99 N/A
BGNE BeiGene, Ltd

-17.60 (-6.43%)

USD24.70B N/A N/A
GMAB Genmab A/S

-0.81 (-2.25%)

USD23.92B 26.59 2.65
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ADPT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 50.43% 74% C 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.43% 74% C 82% B-
Trailing 12 Months  
Capital Gain 59.89% 68% D+ 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 59.89% 68% D+ 81% B-
Trailing 5 Years  
Capital Gain -24.92% 56% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.92% 55% F 25% F
Average Annual (5 Year Horizon)  
Capital Gain 534.81% N/A N/A 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 534.81% N/A N/A 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 1,032.80% N/A N/A 1% F
Risk Adjusted Return 51.78% N/A N/A 69% D+
Market Capitalization 6.27B 94% A 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 43.96 22% F 24% F
Price/Book Ratio 8.19 22% F 16% F
Price / Cash Flow Ratio 30.52 4% F 11% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -17.97% 87% B+ 36% F
Return on Invested Capital -50.05% 60% D- 19% F
Return on Assets -8.25% 87% B+ 28% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.64 42% F 26% F
Short Percent 5.95% 55% F 35% F
Beta 0.49 87% B+ 84% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector